Long-term Survivor of Unresectable Pancreatic Cancer Treated with Concurrent Chemoradiotherapy / 대한소화기학회지
The Korean Journal of Gastroenterology
; : 28-32, 2024.
Article
de En
| WPRIM
| ID: wpr-1045350
Bibliothèque responsable:
WPRO
ABSTRACT
differentiated carcinoma of the pancreas (UPC) is a rare, aggressive pancreatic cancer subtype. In addition, there is limited data on optimal management and patients tend to present with unresectable disease. This highlights the need to explore non-surgical treatments, such as chemotherapy and radiotherapy. In 2017, a 40-year-old male was diagnosed with UPC, presenting with a 6 cm mass in the pancreas, encasing the major arteries, indicative of a locally advanced stage. Histopathology confirmed UPC with osteoclast-like giant cells. After nine cycles of modified FOLFIRINOX chemotherapy and concurrent chemoradiotherapy, treatment was stopped in 2018 because of his declining health. Remarkably, despite the cessation of treatment, by 2023, the tumor had shrunk to 3.5 cm with no metabolic activity indicated by FDG-PET/CT. This six-year survival and response to non-surgical treatment highlight potential new avenues for managing unresectable pancreatic cancer, underscoring the need for further comprehensive studies to evaluate these therapeutic strategies.
Texte intégral:
1
Indice:
WPRIM
langue:
En
Texte intégral:
The Korean Journal of Gastroenterology
Année:
2024
Type:
Article